近5年高被引文献
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
article
Full Text
OpenAlex
1844
FWCI95.9739
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
article
Full Text
OpenAlex
1223
FWCI91.8897
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
article
Full Text
OpenAlex
523
FWCI53.8075
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
article
Full Text
OpenAlex
516
FWCI50.0017
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
article
Full Text
OpenAlex
494
FWCI77.6175
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
article
Full Text
OpenAlex
453
FWCI43.5729
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
article
Full Text
OpenAlex
317
FWCI36.8185
Pharmacological Effects of Cisplatin Combination with Natural Products in Cancer Chemotherapy
article
Full Text
OpenAlex
308
FWCI22.4936
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
review
Full Text
OpenAlex
307
FWCI14.6609